Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (99,997,414)	$ (43,210,337)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities	35,567,205
Warrant related expense	7,649,395
Depreciation and amortization	633,079	504,780
Amortization of deferred revenue	(43,230)	(5,975)
Amortization of bond premiums	205,071	538,200
Amortization of debt issuance costs	547,366	547,366
Amortization of deferred rent	18,062	74,637
Loss (gain) on sale of marketable securities	15,682	(1,844)
Increase (decrease) in allowance for doubtful accounts	(52,561)	31,077
Non-cash expense related to stock compensation	2,593,085	2,840,560
Non-cash decrease in value of life insurance policy		20,566
Other	346,568
Changes in operating assets and liabilities	4,331,955	2,742,797
Net cash used in operating activities	(48,185,737)	(35,918,173)
Cash flows from investing activities:
Purchases of marketable securities	(29,160,546)	(2,749,117)
Proceeds from sales/maturities of marketable securities	42,240,521	38,020,088
Purchases of property and equipment	(829,325)	(1,430,759)
Net cash provided by investing activities	12,250,650	33,840,212
Cash flows from financing activities:
Sale of common stock and warrants, net of related expenses	43,278,473
Exercise of stock options	1,812,780	158,079
Tax withholding payments for stock compensation	(448,625)	(317,390)
Net cash provided by (used in) financing activities	44,642,628	(159,311)
Effect of changes in exchange rates on cash and cash equivalents	(12,698)	(6,194)
Net (decrease) increase in cash and cash equivalents	8,694,843	(2,243,466)
Cash and cash equivalents beginning of period	13,203,625	13,452,775
Cash and cash equivalents end of period	21,898,468	11,209,309
Supplemental disclosure of cash flow information:
Interest paid	$ 4,750,000	$ 4,802,778